Cedars-Sinai scientists have developed an experimental drug called TY1, which is a synthetic version of a naturally occurring RNA molecule in the body. TY1 promotes the repair of damaged DNA by increasing the activity of the TREX1 gene, which helps immune cells remove damaged DNA. This mechanism leads to a reduction in the formation of scars and an improvement in the healing of tissues after heart attacks and other diseases. TY1 was effective in laboratory models of heart attacks, where it improved regeneration and reduced tissue damage. The drug represents a new type of RNA therapy that does not use stem cells, but strengthens the body's natural DNA repair processes. In addition to heart disease, TY1 has the potential to treat autoimmune diseases where the body attacks its own tissues. The researchers are planning further clinical trials to verify the safety and efficacy of TY1 in humans. TY1 is also available in an oral form, which has shown equal efficacy to intravenous administration in experimental models[1][2][3][6][8].